Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study

Departments of Neurological Surgery (M.D.P., S.M.C.) and Neuro-Oncology (M.K.N.), University of California at San Francisco, San Francisco, CA 94143; Departments of Neuro-Oncology (W.K.A.Y.) and Biostatistics (K.R.H.), The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030; Departments of Neurology and Hematology/Oncology, Mayo Clinic Jacksonville, Jacksonville, FL 32224 (K.A.J.); Departments of Medicine (H.I.R.) and Radiotherapy (M.P.M.), University of Wisconsin, Madison, WI 53792; Neuro-Oncology Branch, National Cancer Institute, Bethesda, MD 20892 (H.A.F.); Center for Neuro-Oncology, Dana Farber Cancer Institute, Boston, MA 02115 (P.Y.W.); Neuro-Oncology Program, University of California, Los Angeles, Los Angeles, CA 90095 (T.F.C.); Division of Neuro-Oncology, University of Virginia Health Science Center, Charlottesville, VA 22908 (D.S.); Department of Neurology, University of Michigan, Ann Arbor, MI 48109 (H.S.G., L.J.); Department of Neurology, The University of Texas Southwestern Medical Center, Dallas, TX 75390 (K.L.F.); College of Pharmacy, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 (J.K.); USA